On Apr. 6, 2020, Inovio Pharma announced the U.S. Food and Drug Administration (FDA) had accepted the company’s Investigational New Drug application (NDA) for INO-4800, its DNA vaccine candidate designed to prevent COVID-19 infection.

This NDA acceptance paved the way for Phase 1 clinical testing of INO-4800 in healthy volunteers. The first dosing had begun.